Startups
Your innovation deserves the right partner
OniX connects early-stage biotech and research startups with strategic partners, investors, and industry collaborators. Submit your innovation and let us make the introductions.
From idea to introduction
Share a non-confidential abstract of your therapeutic idea, asset, or product. An OniX expert personally reviews every submission — not an algorithm.
We leverage our database of 100K+ companies, 1.5M+ assets, and 5K+ institutions to identify your best-fit partners, licensees, and collaborators globally.
We facilitate warm introductions to pharma BD teams, investors, and academic collaborators who are actively seeking assets like yours.
Whether it's a funded project, a grant application, or an early-stage concept — we're interested. Innovation at every stage of maturity is welcome.
Submit under NDA if needed. We work with early-stage companies navigating competitive landscapes and understand the need for discretion.
Our network spans 20+ countries and 100K+ companies. Your innovation reaches decision-makers in pharma, VC, biotech, and academic institutions worldwide.
Ready to share your innovation?
Submit a non-confidential abstract. Our team reviews every submission personally.
​
​
Currently looking for Partners for these startups
01 - KTIN Therapeutics
KTIN is pioneering a novel class of therapeutics and medical food additives that restore metabolic balance and performance across species. Leveraging Dr. Karsenty’s decades of NIH-funded work on osteocalcin—a conserved bone-derived protein.​
02 - OniX AH Biotech
OniX AH is developing PegasusX - an oral targeted drug delivery platform using HA-functionalized LNPs to deliver API directly to inflamed tissues.
KTIN: Fundraising Overview and One-Page Summary
​​​
​
​
​
- Animal Health, Food & Nutrition (Series A): $5M
- Muscle Regeneration for Human & Animal Athletes (Series A): $10M
-
Metabolic & Neurological Health in Aging (Series A): $15M
03 - NewCo - TBN
​
NewCo is developing a MusculoPatch system to track muscle degeneration in sport injuries as well as muscle decline in aging.​​​​​​​
NewCo Fundraising overview and One-Pager Summary:
-
MusculoPatch (Pre-seed): $1M
OniX AH: Fundraising Overview and One-Page Summary
-
Animal Health (Series A): $500K – $1M
04 - KTIN Therapeutics: Osteocalcin Analogs
KTIN Therapeutics is a Columbia University spinout developing first-in-class osteocalcin peptide analogs (OCN-PAs) to treat muscle decline (sarcopenia, cachexia, sports recovery), cognitive impairment, metabolic diseases (T2D, obesity), and rare neuromuscular disorders (like OI, SMA, LGMD). Backed by 20+ years of research from Dr. Gerard Karsenty and $10M+ in NIH funding, their platform leverages osteocalcin’s natural, multi-system benefits — enhancing muscle function, cognition, and metabolism simultaneously.
